// App-Quantinova.ai

402 : Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Researchers

Presenter

  • Martin Hutchings

Principal Investigators

  • Rogier Mous

  • Michael Roost Clausen

  • Peter Johnson

  • Kim M Linton

  • Martine E.D. Chamuleau

  • David John Lewis

  • Anna Sureda Balari

  • David Cunningham

  • Roberto S Oliveri

  • Dena DeMarco

  • Brian Elliott

  • Kuo-mei Chen

  • Pieternella J. Lugtenburg

Medical Centers

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • on behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands

  • Vejle Hospital, Vejle, Denmark

  • Cancer Research UK Centre, Cancer Sciences Division, University of Southampton, Southampton, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, VU University Medical Center,Amsterdam,Netherlands

  • Plymouth University Medical School, Plymouth, United Kingdom

  • Institut Catala D'Oncologia. ICO Duran i Reinals, Hospitalet Del Llobregat, Spain

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Genmab, Copenhagen, Denmark

  • Genmab A/S, Princeton, NJ

  • Erasmus MC Cancer Institute, HOVON Data Center, department of Hematology, Rotterdam, Netherlands

Locations

  • Denmark

  • Netherlands

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Cytokine release syndrome

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03625037

Sponsors

  • Genmab

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved